Name: VGN50
Price: 378.00 USD

- Overview
  - Blocks MYC activation.
    VGN50 is a peptide derived from the Kaposi’s sarcoma-associated herpes virus transactivator (K-Rta) sequence, based on the
    binding interface of K-Rta and cellular coactivators. VGN50 interacts with components of coactivators including nuclear receptor coactivator 2 (NCOA2), p300, and SWItch/Sucrose Non-Fermentable (SWI/SNF), the subfamily of ATP-dependent chromatin remodelling complex proteins. VGN50 blocks recruitment of the SWI/SNF complex and results in downregulation of both MYC and MYC-target gene transcription. Expression of MYC is tightly regulated in normal cells but becomes dysregulated in many types of human cancer cells, and application of VGN50 can reduce cell proliferation and selectively kill cancer cell lines in both tissue culture and a xenograft tumour mouse model.
    
    Please contact us for availability.
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Nuclear Receptor Modulators
    
    Alternative Name
    
    K-Rta Peptide 1, Virus de Gann wo Naosu ORF50, K-Rta peptide
    
    Molecular Formula
    
    C121H218N46O32
    
    Molecular Weight
    
    2827.7
    
    Appearance
    
    Freeze dried solid
    
    Purity
    
    >95% by HPLC
    
    Solubility
    
    Soluble in water
    
    Other Properties
    
    Sequence: H-(D)Arg-Lys-Lys-Arg-Arg-Orn-Arg-Arg-Arg-?Ala-Leu-Ser-Ser-Ile-Leu-Gln-Gly-Leu-Tyr-Gln-Leu-Asp-Thr-OH,rKKRR-Orn-RRR-?Ala-LSSILQGLYQLDT
    Modification: D arginine at position 1, ornithine at position 6 and beta alanine at position 10
    
    Storage
    
    Store dry, frozen and in the dark
    
    * Please note: this product can only be supplied to registered research and development facilities, and may be used for in vitro research use only, not for administration to humans or animals.

VGN50

VGN50

We Also Recommend

EPI-X4

Foxy 5

S7